<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01350921</url>
  </required_header>
  <id_info>
    <org_study_id>D5130C00073</org_study_id>
    <nct_id>NCT01350921</nct_id>
  </id_info>
  <brief_title>Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers</brief_title>
  <official_title>A Sequential, Open Label Study to Compare the Pharmacokinetics, Safety and Tolerability of Ticagrelor and Venlafaxine Given Concomitantly in Healthy Subjects Aged 18 to 45 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study evaluates the drug-drug interaction between Ticagrelor and Venlafaxine when taken
      together in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>area under the plasma concentration-time curve during a dosing interval (AUCτ) and observed maximum plasma concentration (Cmax)</measure>
    <time_frame>Multiple assessments during day 8 and 9.</time_frame>
    <description>Venlafaxine and O-desmethylvenlafaxine (ODV) on Day 8 (after multiple dose administration of venlafaxine for 4 days) and Day 9 (after concomitant administration of venlafaxine and ticagrelor):</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Venlafaxine and ODV on Days 8 and 9: time to Cmax (tmax)</measure>
    <time_frame>Multiple assessments during day 1 and 9-11</time_frame>
    <description>Ticagrelor and AR-C124910XX on Day 1 (after single dose administration of ticagrelor) and Day 9 (after concomitant administration of venlafaxine and ticagrelor): area under the plasma concentration-time curve from zero to infinity (AUC), Cmax, tmax and apparent terminal half-life t½λz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of ticagrelor and venlafaxine when given concomitantly by assessments of amount of adverse events</measure>
    <time_frame>Multiple assessments from day -1 do day 12 and a single assessment at follow up visit.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">22</enrollment>
  <condition>Drug Drug Interaction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>90 mg oral immediate release tablets, single dose on days 1 and 9</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlaflaxin</intervention_name>
    <description>37.5 mg oral immediate release tablets, administered twice daily on days 4-8</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a weight of at least 50 kg and a body mass index between 18 to 30 kg/m2

        Exclusion Criteria:

          -  History of clinically significant disease or disorder as judged by the investigator

          -  Any clinically significant illness, medical/surgical procedure or trauma within 4
             weeks of the first administration of drug.

          -  History of haemophilia, von Willebrand´s disease, lupus anticoagulant or other
             diseases/syndromes that may alter or increase bleeding.

          -  History of previous or ongoing psychiatric disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Horrow, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Wilmington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mirjana Kujacic, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca Mölndal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kelli Craven, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Kansas Overland Park US</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>May 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2011</study_first_posted>
  <last_update_submitted>March 29, 2012</last_update_submitted>
  <last_update_submitted_qc>March 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phase 1</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>venlafaxine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

